CliffBio
biologic

Hepcludex

bulevirtide-gmod

Loss of exclusivityMay 2038projected — 12-year biologic exclusivity estimate
CompanyGilead Sciences, Inc.

Drug detail

Brand nameHepcludex
Active ingredientbulevirtide-gmod
Strength8.5MG
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalMay 2026
Marketing statusRx

More from Gilead Sciences, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Hepcludex patent cliff — loss of exclusivity May 2038 | CliffBio